Mitoxantrone has been shown in vitro to exhibit a steep dose-response relationship with respect to the clonogenic survival of acute myeloid leukemia cells. In this report, we show that I-hour exposure of human myeloid leukemia HL-60 and KG-1 cells to mitoxantrone concentrations ranging between 0.1 and 10.0 pmol/L induced internucleosomal DNA fragmentation of approximately 200-bp integer multiples, characteristic of cells undergoing programmed cell death (PCD) or apoptosis. Mitoxantronemediated PCD was associated with a steep inhibition of the clonogenic survival of the leukemic cells. In addition,
ITOXANTRONE is a highly active drug in the treat-M ment of patients with previously untreated and relapsed acute myeloid leukemia (AML).',' Intracellularly, it is known to intercalate between base pairs ofthe DNA helix as well as bind to DNA by nonintercalative electrostatic intera~tion.~ Mitoxantrone treatment produces single and double strand breaks in DNA.4 Some of the protein-associated DNA strand breaks result from a cleavable complex with topoisomerase 11, an enzyme whose activity is markedly inhibited by mit~xantrone.~ In clinical practice, as a single agent or in combination with other drugs, mitoxantrone is generally administered at a dose of IO to 14 mg/m2 as a short intravenous infusion, which produces peak plasma concentrations in the range of 1 .O ~m o l / L .~" Recent in vitro data have shown that high concentrations of mitoxantrone (2 1 .O pmol/L) exhibit a steep dose to inhibition of clonogenic survival relationship toward leukemic blasts.' The mechanism underlying this has not been clearly established. Nonetheless, based on these studies, high-dose mitoxantrone-containing regimens are being tested before autologous bone marrow transplantation and in dose-intensive therapy of relapsed and refractory leukemia. 9J0 Recently, a variety of antileukemic drugs such as Ara-C, nitrogen mustard, cisplatin, and topoisomerase inhibitors, including etoposide and amsacrine, have been shown to induce leukemic cell death by the alternative mechanism of programmed cell death (PCD) or apopto~is."-'~ In contrast to cell necrosis, apoptosis or PCD is an active, energy-dependent process of gene-directed cellular self-destruction that involves fragmentation of genomic DNA into integer multiples of 200 bp units by the activation of a nuclear endonuclea~e.l~*'~ Apoptosis is morphologically characterized by early cell shrinkage, chromatin condensation, nuclear disintegration, cell surface blebbing, and membrane bound apoptotic bodies.I6 Some studies have shown that the modulation of the activity of protein kinase C (PKC) by a variety of agents affects the induction of PCD. '7,18 In addition, the protein encoded by the oncogene BCL-2 has been shown in vitro to block PCD." High levels of expression of BCL-2 protects against apoptosis due to antileukemic drugs, including Ara-C and nitrogen mustard.20,2' Also, Ara-C-induced PCD is associated with altered expression of several genes, including c-jun, c-myc, and BCL-2.'',22,23 Because intracellularly, mitoxantrone-induced PCD was associated with a marked induction of c-jun and significant repression of c-myc and BCL-2 oncogenes. Pretreatment with the protein kinase C stimulator phorbol myristate acetate enhanced mitoxantrone-induced internucleosomal DNA fragmentation, whereas protein kinase C inhibitors staurosporine and H7 had no effect. These findings suggest that PCD is a potential mechanism underlying the steep doseresponse relationship of mitoxantrone to the inhibition of clonogenic survival of acute myeloid leukemia cells. 0 1993 by The American Society of Hematology.
high-dose mitoxantrone is highly active against AML cells, the purpose of the present studies was to determine whether mitoxantrone, like Ara-C, can induce PCD in human myeloid leukemia cells HL-60 and KG-1, and how the modulation of intracellular PKC activity affects this process. An additional aim was to examine the effect of mitoxantrone on c-jun, c-myc, and BCL-2 expression in human myeloid leukemia cells.
MATERIALS AND METHODS
Cells. The human myeloid leukemia cells HL-60 and KG-1 were derived from the original lines.24325 They are maintained in suspension culture as previously described. 26 Mitoxantrone was kindly provided by Lederle Laboratories (Pearl River, NY). Phorbol myristate acetate (PMA), H7, and staurosporine were purchased from Sigma Chemicals (St Louis, MO).
Quantitative and qualitative analyses of internucleosomal DNA fuagmentation. The internucleosomal DNA fragmentation was assayed by a modification of previously described Cells were treated with mitoxantrone for I hour. Alternatively, cells were preincubated with PMA (10 ng/mL for 10 minutes), staurosporine (50 ng/mL for 3 hours), or H7 (50 pmol/L for 3 hours) before mitoxantrone treatment. Staurosporine and H7, but not PMA, were kept in the culture medium during mitoxantrone treatment. After these incubations, cells were washed and incubated in drug-free media for an additional 4 hours. At the end ofthis incubation, cells were pelleted and washed with phosphate-buffered saline (PBS) at 4°C and disrupted by suspension for 20 minutes at 4°C in Drugs. For personal use only. on October 25, 2017. by guest www.bloodjournal.org From 10% 12-0-tetradecanoylphorbol-I 3-acetate (TCA), the microfuge tubes were centrifuged for 5 minutes. The supernatant was discarded and the pellet was resuspended in I mL of 100% ethanol at 4°C and incubated at -20°C. After another centrifugation, the pellet was treated with 500 pL of I N sodium hydroxide to hydrolyze RNA and incubated at 37°C for I hour, or until it was resuspended.
From the Division of
The reaction mixture was incubated for 15 minutes on ice. treated with 1.5 mL of 20% TCA for 30 minutes at 4OC, and then centri- For personal use only. on October 25, 2017. by guest www.bloodjournal.org From hol extraction and precipitation with ethanol. and electrophoresed in I% agarose with IX TAE runner buffer containing ethidium bromide. The electrophoresed DNA was transferred overnight to nylon membranes by standard capillary methods. Blots were UV cross-linked and hybridized at 55°C overnight in 5070 formamide/ IO% dextran sulfate/l% sodium dodecyl sulfate (SDS)/5.6% sodium chloride containing denatured salmon sperm DNA. Separately, fragmented DNA from drug-treated leukemic cells was used to make a cDNA probe labeled by the random hexamer priming system by Prime-a-Gene. Blots were washed for 30 minutes at 27°C in 2X SSC/O. 1% SDS and for 30 minutes at 65°C in 0. I X SSC/O. 1% SDS, and autoradiographed for IO minutes to 5 hours at -70°C.
-
RNA ertracrion. Total cellular RNA was extracted by the guanidine thiocyanate-phenol-chloroform method."' After exposure to the designated concentrations and schedule of mitoxantrone (see above), cells were washed with PBS and homogenized in GIT buffer (4 mol/L guanidine isothiocyanate. 2 mol/L sodium acetate. pH 4.
0. I mol/^ 2-mercaptoethano~), ~h~ homogenate was then treated with 1o9/o Sarkosyl and 2 mol/L sodium acetate, and the total cellular RNA extracted through a pheno1:chloroform:isoamyl alcohol suspension ( E 2 4 I ) and subsequent centrifugation. The resulting 
cells were washed and incubated for an additional 4 hours in drug-free media. Subsequently, cells were plated in microwells and colony-forming emciency was detemined after 1 0 days of incubation (see text). Data wints on the cu, , , e represent mean of two experiments in which cells were plated at different densities in 16 replicates.
fuged at 4OC for IO minutes at 1.500 rpm. The pellet was vortexed or sonicated and DNA was hydrolyzed with 1 mL of 5% perchloric acid (PCA) for 15 minutes at 90°C with frequent vortexing to break up the pellet and release DNA from the pellet. Subsequently, the reaction mixture was centrifuged at 3,000 rpm and the supernatant was treated overnight at 37°C with 2 mL of Burton's reagent that uses a diphenylamine reaction. The absorbance at 600 nm was compared with that of 0 to 250 pg/mL of DNA as standard. using linear regression. The quantity of fragmented DNA in the supernatants was expressed as a percentage of total DNA from 2 X IO' cells.
For qualitative DNA analysis, I X IO6 cells were treated with mitoxantrone, as described above. At the end of the incubations, cells were washed in PBS and resuspended in the lysis buffer. as above. The suspension was centrifuged and DNA was extracted from the supernatant by treatment with phenol, and chloroform/ isoamyl alcohol (2594: l).2'.28 To the upper aqueous layer placed in a fresh tube, 50 p L of 3 mol/L sodium acetate and I mL of 100% ethanol at 4°C was added to precipitate the DNA. The mixture was vortexed and incubated for 30 to 60 minutes at -70°C. After a cold centrifugation for 30 minutes at 10.000 rpm, the supernatant was discarded and the pellet was resuspended in 0.5 mL of Tris EDTA (TE) buffer at pH 8.0. After adding IO pL of DNase-free RNase A to the suspension, it was vortexed and incubated for 30 minutes at 37°C. To this, 50 pL of 5 mol/L NaCl was added and the phenol/ chloroform/isoamyl alcohol extraction was repeated. DNA was precipitated with ethanol as above and centrifuged, and the pellet was dried. DNAsamplesweremixedwith 16pL(per5 X 106cells)ofTE (pH 8.0) loading buffer and 2 pL of 5X tracking dye containing glycerol, bromophenol blue, and xylene cyanol. The reaction mix was loaded into wells of a I% agarose gel, and electrophoresed in a I X Tris-acetate-EDTA (TAE) running buffer containing ethidium bromide. DNA was separated over 90 minutes at 60 V and the bands were visualized by UV illumination.
Soitthem hlor method ,for the ewlitarion ef DNA ,fiagmenlalion. To improve the sensitivity of detecting DNA fragmentation associated with apoptosis, a slightly modified version of a PreVi-OuSlY described Southern blot method was Used.29 DNA from the leukemic cells treated with the designated concentration of the drugs was isolated and purified by pheno1:chloroform:isoamyl alco- RNA pellet was washed with absolute ethanol, dissolved in diethyl pyrocarbonate-treated water. and stored at -20°C until used. Total RNA extracted by this procedure has an A260/A280 ratio of 1.95. The level of BCL-2. c-jim. c-my, and 8-actin RNA is determined by Northern blot analysis (vide intra) using the following "P-la- RNA hybridization analysis was performed as previously described." Total RNA ( I O p g ) was obtained as described above, was mixed with electrophoresis sample buffer (100% deionized formamide. 37% formaldehyde. IOX MOPS, glycerol, 4% bromophenol blue. 4% xylene cyanol). was denatured at 65°C for I5 minutes. and was run on a I .O% agarose gel in 1 X MOPS buffer. The RNA in the gel was denatured with 0.05 N NaOH/O. I5 mol/L NaCl for 30 minutes and neutralized with 0. I mol/L Tris (pH 7.5)/0.15 mol/L NaCl for 30 minutes. The gel was then placed in contact with nitrocellulose filter and the RNA was transferred to the solid support on a PosiBlot Pressure Blotter (Stratagene) at 80 psi for 2 hours. The RNA wascross-linked to the filter by a UV cross-linker (Stratagene). Prehybridization and hybridization of the RNA was performed in low stringency conditions. The nitrocellulose membrane was prehybndized overnight at 55°C in the following solution containing deionized formamide. 50% dextran sulfate. 10% SDS. and 100 pg/mL salmon sperm DNA. Random-primed, 'zP-labeled cDNA probes were heat-denatured. cooled, and added to the buffer and hybridized for I8 to 72 hours at 55°C. The hybridized blots were washed twice in 2X SSC (sodium chloride and sodium citrate). 0. I% SDS at 65°C for I5 minutes per washing, and twice in 0. I X SSC. 0.1% SDS at 65°C. again for 15 minutes per washing. The blots were then exposed to Kodak X-Omat AR films with intensifying screens (Eastman Kodak, Rochester, NY). The developed films were scanned by densitometry.
Colony citlritrc. of leirkmic cc.lls. The colony growth of the leukemic cells was determined by a minor modification ofa previously described method.'(' Briefly, after incubation of log growth phase cells with the different concentrations of mitoxantrone for I hour. cells were washed twice in RPMI 1640 medium and incubated at 37°C in a 5% C 0 2 fully humidified incubator for an additional 4 hours. Subsequently, serial dilutions ofcells were plated at cell densities ranging from I to I X IO4 cells/well in 96-well U-bottomed microplates (Baxter) in I6 replicates in a plating medium consisting of RPMI 1640. 20% fetal bovine serum (FBS), and 0.15% agarose. The plates were incubated at 37°C in 5% COz atmosphere for IO days. At the end of this incubation. colony-forming efficiency was determined in each well. Maximum likelihood analysis was performed by using the formula described by T a s~e l l .~~ S/ali.s/ical ana1v.si.s. Significant differences between values obtained in a population of leukemic cells (HL-60 or KG-I) treated with different experimental conditions were determined by paired t-test analyses. HL-60 cells were exposed to mitoxantrone (1 .O pmol/L), staurosporine (50 ng/mL for 4 hours), or H7 (50 pmollLfor4 hours) alone. Altematively, cells were exposed to staurosporine or H7 for 3 hours, followed by concurrent treatment with mitoxantrone for 1 hour. After treatment with mitoxantrone, cells were washed and kept in drugfree medium for 4 hours. Subsequently, cells were pelleted and total cellular RNA was extracted. Northern blots of the electrophoresed RNA (20 pg) were hybridized with 32P-CTP-labeled randomprimed cDNA probes of c-myc, c-jun, and @-actin genes. Lane 1 has RNA from untreated, control  cells. lanes 2 , 3 , Fig 2, by using the Southern blot method with a significantly greater sensitivity (50-to 1 OO-f~ld).~~ oligonucleosomal DNA fragmentation could be detected after treatment with 20.1 pmol/L (Fig 2, lanes 2 and 3) but not after treatment with 0.01 pmol/L mitoxantrone, whereas high mitoxantrone concentrations, 20 pmol/L and above, produced random DNA fragmentation characterized by a smear (Fig 2, lane 5) on the blot. Quantitative analyses of the fragmented DNA in the supernatant of the lysed HL-60 and KG-I cells expressed as the mean percent of the total starting DNA are shown in Fig 3. Figure 3 shows that a marked increase in the DNA fragmentation was observed when HL-60 and KG-I cells were treated with greater than 0.1 pmol/L mitoxantrone, and a maximal increase in the amount of internucleosomal DNA fragmentation occurred when the cells were exposed to IO pmol/L mitoxantrone. Higher concentrations of mitoxantrone did not further increase the DNA fragmentation (data not shown). Plasma mitoxantrone concentrations in the range of 1 to 10 pmol/L are achievable with drug regimens containing high-dose mit~xantrone.~." These concentrations of mitoxantrone produced a several log decline in clonogenic survival of HL-60 cells, as shown in Fig 4. These concentrations have also been previously demonstrated to have a steep dose to the inhibition of clonogenic survival relationship for fresh AML blasts.' Figure 5 shows the results of the Northern blot analysis of RNA from cells treated with different concentrations of mitoxantrone and hybridized to c-myc, c-jun. BCL-2, and pactin c-DNA probes. Control HL-60 cells exhibited low BCL-2 and high c -m y expression, whereas c-jzm expression in these cells was low to undetectable ( Fig 5, lane 1) . Figure  5 Recent studies have indicated that a modulation of intracellular PKC activity may affect the internucleosomal DNA fragmentation and apoptosis mediated by a variety of d r~g s . '~* '~ Based on previous studies that have shown that a short exposure to PMA (I I5 minutes) produces PKC stimulation but longer exposures and that long-term treatment inhibits PKC activity, we selected PMA pretreatment at 10 ng/mL concentrations for 10 minutes as the optimal PKC stimulatory dose for our experiment^.^^ Figure 6 shows that the treatment of HL-60 cells with PMA repressed c-mjr expression by approximately threefold, but produced a 1.5fold increase in c-jzm expression (lane 3). Figure 6 also shows that pretreatment with PMA reproducibly further enhanced mitoxantrone-( I .O pmol/L) mediated induction of c-jun by approximately twofold and the inhibition of c-mjr expression by approximately eightfold (lane 4 1' lane 2) . However, PMA pretreatment did not affect BCL-2 repression due to mitoxantrone (data not shown). Nonetheless. prior exposure to PMA (Fig 6, lane 4) produced increased intensity of the bands on the DNA fragmentation ladder induced by 1.0 pmol/L mitoxantrone alone (Fig 6, lane 2) . This was confirmed by a significant quantitative increase in the mean DNA fragmentation with mitoxantrone alone from 30.5% f 1.2% to 39.4% f 1.5% (mean * SEM of 3 experiments, P < .05) observed after treatment with PMA followed by mitoxantrone. These findings do not necessarily establish a direct causal relationship between the PMAinduced enhancement in mitoxantrone-mediated c-jzm in-For personal use only. on October 25, 2017. by guest www.bloodjournal.org From duction and the increase in the DNA fragmentation. PMA pretreatment also produced a 1.6k 0.1-fold increase in the mitoxantrone-mediated inhibition of clonogenic survival of HL-60 cells. However, the viability of cells, as detected by trypan blue exclusion method, just before DNA extraction for the DNA fragmentation studies, was 295%. This is consistent with the previously published observations that internucleosomal DNA fragmentation precedes loss of membrane integrity and viability.''."'6 We also examined the effect of PKC inhibitors staurosporine and H7 on mitoxantrone-induced alterations in c-jun, c-myc, and BCL-2 expression as well as the internucleosomal DNA fragmentation. Although both compounds inhibit PKC, H7 is also an equally potent inhibitor of CAMP-and cGMP-dependent protein kinases. 35 (Fig 7, lane 4) or H7 (Fig 7, lane 6) had no significant effect on mitoxantrone-induced alterations in cjun expression, although c-myc repression was further enhanced by staurosporine but not by H7 pretreatment. Staurosporine or H7 alone had no significant effect on BCL-2 expression, and they also did not affect BCL-2 repression due to mitoxantrone (data not shown). Importantly, these PKC inhibitors had no effect on mitoxantrone-induced internucleosomal DNA fragmentation (data not shown). These results suggest that, whereas the PKC stimulator PMA enhanced mitoxantrone-induced c-jun expression and internucleosomal DNA fragmentation, PKC inhibitor staurosporine did not inhibit these effects of mitoxantrone. It should also be noted that in both Figs 6 and 7 c-jun RNA expression in untreated HL-60 cells was greater than those used in the experiments whose results have been presented in Fig 5. This discrepancy may be due to the differences in cell density and differentiation status, or due to slight differences in the duration of washing of control HL-60 cells with serum-free medium, in different experiments, before exposure to the various treatment conditions.
Norrhern hlor ana1jsi.s.

RESULTS
The effect of treatment with mitoxantrone
DISCUSSION
Previous in vitro studies have shown that mitoxantrone concentrations between 0.1 and 10 Wmol/L exhibit a steep dose-response relationship with respect to the clonogenic survival of AML blasts as well as for their self-renewal capacity.* These concentrations are clinically achievable with the regimens containing high-dose mitoxantrone that have been shown to have significant clinical activity in leukem i a~. ' ,~,~, '~ The cytotoxic effect of mitoxantrone is thought to be related to its binding to DNA as well as to its inhibition of DNA topoisomerase I1 by trapping it in a cleavable, covalent, topoisomerase-DNA ternary ~omplex.'~ The accumulation of mitoxantrone-stabilized cleavable complexes that sequester DNA strand breaks is also associated with the inhibition of DNA synthesis and the arrest of cells in G, phase of the cell cy~le.'~,~' Although other mechanisms for mitoxantrone-induced DNA damage involving free radical production and the inhibition of DNA helicase I1 activity have been p r o p~s e d , '~,~~ the mechanisms underlying its steep dose-response relationship for the inhibition of clonogenic survival of AML blasts has not been elucidated. Recently, a variety of DNA interactive drugs have been shown to induce leukemic cell death by the alternative process of PCD.",'2,2'. 23 The biochemical hallmark of this genedirected, active form of cell death is the nuclear endonuclease-mediated internucleosomal DNA fragmentati~n.'~.'~ Previous studies have correlated the induction of internucleosomal DNA fragmentation by the antileukemic drugs with their inhibition of clonogenic survival of leukemic cells. ' In these studies, the drug-induced intemucleosomal DNA fragmentation was also associated with marked induction of c-jun and downregulation of the expression of BCL-2 and c-myc genes.",23 In the present report, we have shown that the concentrations of mitoxantrone ranging between 0. l and 10 pmol/L produce a steep decline (by several logs) in clonogenic survival of myeloid leukemia cells that corresponds with increasing amounts of internucleosomal DNA fragmentation characteristic of PCD. This DNA fragmentation is associated with a marked induction of c-jun but a decrease in BCL-2 and c-myc oncogene expression. However, it should be noted that, with respect to c-jun, only an association and not a cause and effect relationship has been established between its induction and the DNA fragmentation associated with apoptosis.
The gene product of the oncogene BCL-2 is an inner mitochondrial membrane protein that blocks PCD.I9 In pre-B-leukemia cells, high levels of BCL-2 expression block glucocorticoid-induced apopt~sis.~' Recently, the transfection and stable expression of BCL-2 in thymocytes renders these cells relatively resistant to a variety of drugs known to induce internucleosomal DNA fragmentation associated with apoptosis.2' It has also been previously reported that in the cells expressing low levels of BCL-2 a continuous decline in c-myc expression may be responsible for their growth arrest and apopto~is.~* Our findings show that HL-60 cells express relatively low levels of BCL-2. Also, 1.0 and 10.0 pmol/L mitoxantrone produced a marked inhibition in BCL2 expression with a concomitant decline in c-myc expression, thereby facilitating the induction of apoptosis. It is also noteworthy that HL-60 cells lack the expression of wild-type tumor suppressor p53 gene, which has been shown to induce apoptosis without differentiation when transfected into myeloid leukemia cell^.^^,^' Therefore, it is conceivable that the myeloid leukemia cells that lack a functioning wildtype p53 gene and possess low levels of BCL-2 express may be particularly susceptible to the induction of PCD by increasing concentration of DNA interactive drugs such as Ara-C and mitoxantrone.
Because PCD is an active process of gene directed cellular self-destruction, the molecular signals that govern this process and are triggered before the induction of apoptosis by mitoxantrone would be important targets for modulation in an attempt to selectively facilitate PCD in myeloid leukemia cells. Although Ara-C has been shown to activate PKC For personal use only. on October 25, 2017. by guest www.bloodjournal.org From and induce c-jun and AP-1 transcription factors," the molecular signal responsible for mitoxantrone-induced c-jun expression remains to be elucidated. Although the stimulation of PKC has been shown to block glucocorticoids induced PCD in lymphocytes, in sarcoma or leukemic cells it has resulted in the augmentation of doxorubicin-induced PCD. '7,'8,4' Our results show that pretreatment with PKC stimulator PMA enhances mitoxantrone-induced c-jun expression and the intemucleosomal DNA fragmentation.
However, this occurred without significant effect on BCL-2 repression seen with mitoxantrone alone, which suggests that, in addition to BCL-2, other genes may have an important role in regulating apoptosis in leukemic cells. Unlike what has been observed for Ara-C,44 PKC inhibitors staurosporine and H7 neither inhibited mitoxantrone-induced cjun expression nor affected mitoxantrone-mediated internucleosomal DNA fragmentation characteristic of PCD. These discordant results suggest that the intracellular PKC activity and c-jun expression do not directly control or may not be the sole regulators of mitoxantrone-induced internucleosomal DNA fragmentation of apoptosis.
High-dose Ara-C and mitoxantrone combination is a n effective regimen for the treatment of AML.'** The findings reported here highlight a possible mechanism for the antileukemic activity and the steep dose response effect of highdose mitoxantrone against AML. Taken together with similar observations reported for high-dose Ara-C, these results offer an explanation for the effectiveness against AML of the salvage regimen incorporating the two drugs. In addition, our results also underscore a mechanism of cell death mediated by these drugs that can potentially be modulated to augment their antileukemic activity.
